When IL-17 inhibitors fail: real-life evidence to switch from secukinumab to adalimumab or ustekinumab.

Psoriasis is a chronic, systemic inflammatory disease that in the moderate to severe forms may benefit of biologics, namely TNF and IL-12/23 and IL-17 inhibitors. Loss of response, lack of response or discontinuation due to adverse events represent a concrete therapeutic challenge for dermatologists...

ver descrição completa

Na minha lista:
Detalhes bibliográficos
Publicado no:Dermatol Ther
Main Authors: Damiani, Giovanni, Conic, Rosalynn RZ, de Vita, Valerio, Costanzo, Antonio, Regazzini, Roberto, Pigatto, Paolo DM, Bragazzi, Nicola L, Pacifico, Alessia, Malagoli, Piergiorgio
Formato: Artigo
Idioma:Inglês
Publicado em: 2018
Assuntos:
Article
Acesso em linha:https://ncbi.nlm.nih.gov/pmc/articles/PMC6445726/
https://ncbi.nlm.nih.gov/pubmed/30515970
https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1111/dth.12793
Tags: Adicionar Tag
Sem tags, seja o primeiro a adicionar uma tag!

Registos relacionados